Table 1.
Characteristics of the Participants at Baseline.*
| Characteristic | Mifepristone-Pretreatment Group (N = 149) | Misoprostol-Alone Group (N = 151) |
|---|---|---|
| Age — yr | 30.7±6.3 | 30.2±6.0 |
| Race or ethnic group — no. (%)† | ||
| Black | 65 (43.6) | 67 (44.4) |
| White | 57 (38.3) | 52 (34.4) |
| Hispanic | 38 (25.5) | 38 (25.5) |
| Asian | 9 (6.0) | 11 (7.3) |
| Other | 18 (12.1) | 21 (13.9) |
| Education‡ | ||
| Some grade school or high school | 10 (6.8) | 17 (11.3) |
| High-school diploma or GED | 46 (31.1) | 56 (37.1) |
| Some college or post–high-school education | 92 (62.2) | 78 (51.7) |
| Medical insurance‡ | ||
| None | 13 (8.8) | 11 (7.3) |
| Medicaid or Medicare | 64 (43.2) | 78 (51.7) |
| Private insurance | 71 (48.0) | 62 (41.1) |
| Gravidity | ||
| 1 | 37 (24.8) | 32 (21.2) |
| 2 | 36 (24.2) | 27 (17.9) |
| ≥3 | 76 (51.0) | 92 (60.9) |
| Parity | ||
| 0 | 63 (42.3) | 52 (34.4) |
| ≥1 | 86 (57.7) | 99 (65.6) |
| Living children | 87 (58.4) | 94 (62.3) |
| Previous miscarriage | 53 (35.6) | 52 (34.4) |
| Gestation | ||
| 4–5 wk | 15 (10.1) | 10 (6.6) |
| 6 wk | 44 (29.5) | 38 (25.2) |
| 7 wk | 34 (22.8) | 46 (30.5) |
| 8 wk | 31 (20.8) | 34 (22.5) |
| 9 wk | 14 (9.4) | 15 (9.9) |
| 10–12 wk | 11 (7.4) | 8 (5.3) |
| Diagnosis | ||
| Anembryonic gestation | 40 (26.8) | 37 (24.5) |
| Embryonic or fetal death | 109 (73.2) | 114 (75.5) |
| Any bleeding before randomization | ||
| Yes | 18 (12.1) | 17 (11.3) |
| No | 111 (74.5) | 119 (78.8) |
| Unknown | 20 (13.4) | 15 (9.9) |
*
Plus–minus values are means ±SD. Participants assigned to the mifepristone-pretreatment group received 200 mg of mifepristone, administered orally, followed by 800 μg of misoprostol, administered vaginally approximately 24 hours later, and those assigned to the misoprostol-alone group received 800 μg of misoprostol alone, administered vaginally. There were no significant differences between the groups in any of the characteristics listed. Percentages may not sum to 100 because of rounding.
†
Race and ethnic group were reported by the participants.
‡
One participant in the mifepristone-pretreatment group was excluded because of missing values.